Purpose: The purpose of this study was to measure health-care resource utilization and costs in treatmentadherent, previously seizure-free patients with epilepsy who were treated in the inpatient/emergency room (ER) setting for new-onset seizures, compared with matched controls. Methods: The study used a retrospective case/control study design using administrative claims from the IMS PharMetrics™ database. We identified adult patients with epilepsy with 1+ ER visit/hospitalization with primary diagnosis of epilepsy between 1/1/2006 and 3/31/2011, preceded by 6 months of seizure-free activity and antiepileptic drug (AED) treatment adherence (≥80% of days covered by any AED); the first observed seizure defined the "breakthrough" seizure/index event. Treatment-adherent patients with epilepsy without any ER/hospital admission for seizures served as controls: an outpatient epilepsy-related medical claim within the selection window was chosen at random as the index date. The following were continuous enrollment requirements for all patients: ≥12-month pre-and ≥6-month postindex. Each case matched 1:1 to a control using propensity score matching. All-cause and epilepsy-related (epilepsy/convulsion diagnosis, AED pharmacy) resource utilization and unadjusted and adjusted direct health-care costs (per person, 2012 US dollars (USD)) were assessed in a 6-month follow-up period. Principal results: There were 5729 cases and 14,437 controls eligible. The final sample comprised 5279 matched case/control pairs. In unadjusted analyses, matched cases had significantly higher rates of all-cause hospitalization and ER visits compared to controls and significantly higher total all-cause direct health-care costs (median $12,714 vs. $5095, p b 0.001) and total epilepsy-related costs among cases vs. controls (median $7293 vs. $1712, p b 0.001), driven by higher inpatient costs. Among cases, costs increased with each subsequent seizure (driven by inpatient costs). Cases had 2.3 times higher adjusted all-cause costs and 8.1 times higher adjusted epilepsyrelated costs than controls (both p b 0.001). Conclusion: Inpatient/ER-treated breakthrough seizures occurred among 28.4% of our treatment-adherent study sample and were associated with significant incremental health-care utilization and costs, primarily driven by hospitalizations. Our findings suggest the need for better seizure control via optimal patient management and the use of effective AED therapy, which can potentially lower health-care costs.
Introduction
Epilepsy is a chronic brain disorder characterized by recurrent seizures caused by abnormal neuronal activity, impacting more than 2.3 million adults in the US [1] . Therapeutic options for better seizure control include antiepileptic drug (AED) therapies such as sodium channel blockers and gamma-aminobutyric acid (GABA) enhancers, and in the case of drug-resistant epilepsy, surgical therapies such as vagal nerve stimulation (VNS) and focal resection [2, 3] . Treatment choice is primarily based on the efficacy of an AED for a specific seizure type, but other factors such as tolerability, age, sex, and comorbidities are also important to consider [4, 5] .
Approximately two-thirds of newly diagnosed patients with epilepsy will become seizure-free with AED therapy (typically defined as seizure-free for ≥1 year), and for most, seizure control will be achieved with the use of their first or second AED regimen [2] . However, at least one-third of patients may continue to experience seizures, sometimes referred to as "breakthrough seizures". Breakthrough seizures have been described in the literature as seizures that happen suddenly and unexpectedly after a period of seizure freedom [6] , but a clear clinical definition within guidelines is lacking [4, [7] [8] [9] . Breakthrough seizures are most often discussed as a potential consequence of a change in AED, or nonadherence to prescribed AEDs; however, other potential precipitants include onset of an infection, sleep deprivation, severe emotional stress, and provocative environmental factors such as flashing lights or playing video games [6, 10, 11] . There can be severe consequences of breakthrough seizures including risk of accidents, fractures or head injuries, emergency room (ER) visits, and hospitalization, as well as an associated increase in health-care costs.
The economic burden of epilepsy is well established in the literature [12] . Higher health-care costs have also been associated with increasing number of seizures from initial epilepsy diagnosis [13] . Patients with refractory epilepsy (defined as use of ≥3 AEDs in a calendar year) have been found to have higher costs compared to patients with wellcontrolled epilepsy among patients with partial onset seizures (POS) [14] . Patients with uncontrolled epilepsy (defined as addition of an AED to an existing regimen) have been found to have higher costs compared to patients with stable epilepsy [15] . Patients with uncontrolled epilepsy (defined as ≥2 changes in AED therapy, followed by ≥1 epilepsy-related ED visit/hospitalization within 1 year) have been found to have higher costs compared to patients with well-controlled seizures (no AED change and no epilepsy-related ER visit/hospitalization) [16] . Additionally, one study assessed patients who received epilepsy-related treatment in emergent care settings after a period of AED adherence and seizure control and found higher costs in the 6 months following the event compared to the 6 months prior [17] .
The objective of this study was to evaluate the direct cost impact of breakthrough seizures among AED-adherent patients. We identified patients with epilepsy in a US managed care population with and without evidence of a breakthrough seizure after a period of sustained control and compared all-cause and epilepsy-related health-care resource utilization and direct health-care costs between matched cohorts in the 6-month follow-up period. Additionally, we evaluated the impact of seizure frequency on all-cause health-care resource utilization and direct costs among cases. These findings would help quantify the frequency of breakthrough seizures as well as the direct clinical and economic consequences caused by breakthrough seizures, currently missing from existing literature.
Materials and methods

Data source
This retrospective database analysis utilized data from the IMS LifeLink Health Plan Claims database (PharMetrics™), comprising fully adjudicated medical and pharmaceutical claims for approximately 70 million unique patients from over 70 health plans across the US at the time of the study. Enrollees represented include those covered by employer-sponsored plans and government-sponsored but commercially administered Medicaid and Medicare plans as well as individuals purchasing coverage in the marketplace. Among payer types for all enrollees, 79% have a commercial plan while 10% are self-insured. The remaining 11% comprise Medicaid, Medicare Cost, Medicare Risk, or State Child Health Insurance. The PharMetrics database is most represented by the Midwest (34%) and South (31%), followed by the Northeast (19%) and then West (16%). The database is overrepresented by the Midwest and slightly underrepresented by the South and West: compared to the 2010 US census, the US population was highest in the South (37%), followed by the West (23%) and Midwest (22%), and then the Northeast (18%) [18] . Records are representative of the national, commercially insured population on demographic measures, including age and gender. Data elements include patient and plan type/enrollment, as well as inpatient and outpatient diagnoses (in ICD-9-CM format) and services/procedures, and both retail and mail order prescription records. Allowed, charged, and paid amounts are available for all services rendered as well as dates of service for all claims. The data are longitudinal, with an average member continuous enrollment period of more than two years, providing complete data capture. Patient data are de-identified following the Health Insurance Portability and Accountability Act (HIPAA); therefore, this study was exempt from Institutional Review Board review.
Cohort selection
Medical and pharmacy claims were assessed to identify adult (18 + years) cases and controls based on seizure activity within the sample selection window (July 1, 2006 to March 31, 2011). Because there is no single clinical definition or clinical diagnosis code for breakthrough seizure, we developed our definition based on a review of the literature and clinical input. We used our breakthrough seizure definition as a proxy to identify the subset of patients who experience breakthrough seizures and receive inpatient/ER care. Similar to two studies by Zachry et al., our breakthrough seizure definition required an epilepsy-related inpatient or ER admission following a combined period of seizure control and AED adherence [17, 19] . Breakthrough seizures were identified as an ER or inpatient admission with a primary diagnosis of epilepsy (ICD-9-CM code 345.x excluding 345.6 [infantile spasms]), occurring in patients who had no evidence of a seizure and with ≥80% of days covered by any AED (proportion of days covered (PDC)) during the 6-month preindex period (80% adherence is a commonly used measure of "good" adherence within the literature). Patients meeting the criteria for a breakthrough seizure were identified as cases. The first seizure eligible as a breakthrough seizure within the sample selection window was chosen as the index date for cases. These requirements help provide confidence that the observed breakthrough seizure, occurring after a period of sustained seizure control and medication adherence, more likely resulted due to AED inefficacy rather than nonadherence.
The control group consisted of patients with epilepsy who had no evidence of a seizure in their entire available time within the database and who met the same AED adherence requirements as cases. A random outpatient medical claim (i.e., physician or facility visit) containing a primary diagnosis of epilepsy during the selection window was selected as the index date for controls in order to help ensure that controls were captured in all stages of the disease.
All patients were required to have ≥12-month preindex continuous health plan enrollment with ≥1 epilepsy diagnosis within that period. Patients were further required to have ≥ 6-month continuous health plan enrollment postindex (the follow-up period). The continuous health plan enrollment criteria were required to eliminate the impact of insurance coverage interruptions and to ensure visibility into a patient's health-care utilization and costs under his or her plan's coverage. Patients with incomplete health plan data (e.g., Medicare Fee-forService plan) were excluded.
Propensity score matching was utilized on the final eligible sample to control for demographic and clinical factors which may otherwise impact resource utilization and costs, aside from the event of interest (seizure activity resulting in ER/inpatient care). Propensity score matching is a common regression modeling technique used in retrospective database analysis to adjust for differences between study cohorts. After examining unadjusted baseline patient characteristics, cases and controls were matched 1:1 using a "nearest neighbor" approach, defined by a minimal difference (e.g., b 0.001) in the fitted probability of experiencing a breakthrough seizure on the following characteristics: age group, gender (although not significant), payer type, physician specialty, and the following characteristics measured over the 6-month preindex: Charlson Comorbidity Index, essential hypertension, and all-cause health-care costs (in the 6-month preindex).
Main outcome measures
Baseline clinical characteristics were calculated using medical and pharmacy claims from the 6-month preindex period. The following measures were evaluated over the 6-month follow-up period:
• Antiepileptic drug adherence was measured for matched cases and controls using PDC. Proportion of days covered was measured until the end of the last supply for the patient's index AED therapy over the 6-month follow-up period. Proportion of days covered was calculated with the total number of days supplied for a patient's index AED therapy as the numerator, and the number of days until the end of the last supply as the denominator. Proportion of days covered was capped at 100%; ≥80% PDC by any AED was considered adherent.
• All-cause and epilepsy-related health-care resource utilization and direct health-care costs in the 6-month follow-up period were assessed and compared between matched cases and controls. Health-care service categories included outpatient pharmacy (retail and mail), hospitalizations, ER visits (not resulting in hospital admission), and outpatient care (physician visits/procedures). ○ Epilepsy related claims were inclusive of AED therapy and medical claims with an epilepsy or convulsion diagnosis (ICD-9-CM 345.x, 780.3 in any position). ○ The number of unique AED medications was defined at the class level (anticonvulsants (miscellaneous), anticonvulsant combinations, benzodiazepines, carbamates, GABA modulators, hydantoins, succinimides, valproic acid) while the number of unique non-AED medications was defined at the therapeutic class level (i.e., 10-digit GPI code). ○ Total costs consisted of both total outpatient pharmacy and total medical care (inpatient, ER, outpatient) costs. Costs were reported in 2012 US dollars (USD) as costs per patient and evaluated on a per cohort member basis (inclusive of all patients whether they experienced utilization in a service category or not). ○ All-cause resource utilization and cost outcomes by seizure frequency (1, 2, 3+ seizures) in the 6-month follow-up period were reported descriptively among cases.
Statistical/analytical methods
Descriptive and summary statistics were reported. Independent statistical testing was used to evaluate differences: pairwise comparisons (chi-square) for categorical measures and the Wilcoxon rank-sum test conducted on the median for continuous measures. Generalized estimating equation (GEE) models were developed to adjust all-cause and epilepsy-related costs for baseline covariates. A p-value b 0.05 was considered statistically significant. All analyses were conducted using SAS version 9.1 (Cary, NC).
Results
Baseline demographic and clinical characteristics
A total of 20,166 patients met our initial selection criteria, representing an occurrence of breakthrough seizures among 28.4% (5729 cases; 14,436 controls) of our study population during the 5-year study window. Prior to propensity score matching, cases and controls were significantly different (at p b 0.001) on a number of demographic and clinical characteristics. Cases were significantly younger (mean age 42.1 and 44.8 years [median 43 vs. 47 years]), fewer were commercially insured (74.1% and 80.7%) and more were Medicaidinsured (9.2% vs. 4.0%), fewer had a CCI score of 0 (62.4% vs. 72.5%), and fewer cases used 1 unique AED class in the 6-month preindex (52.5% vs. 70.7%) (use of N1 unique AED class indicates either a switch or combination therapy of 2 or more AED classes); however, it is possible that patients using only 1 unique AED class switched or received combination therapy of 2 different AEDs in the same class. Cases also had higher 6-month preindex total all-cause health-care costs (mean $14,663 vs. $7115 [median $6408 vs. $3276]).
Following 1:1 propensity score matching, the final sample consisted of 5279 matched cases and 5279 matched controls who were similar in baseline demographic and clinical characteristics (see Table 1 ). A few significant differences remained between cases and controls. Cases used more unique AED classes in the 6-month preindex: 39.8% with 2 AED classes and 13.1% with 3 + AED classes, compared to 32.8% and 7.7% of controls, respectively (p b 0.0001). A number of AED drug classes used in the 6-month preindex were more frequent among cases compared to controls, including benzodiazepines (33.6% vs. 25.5%) and hydantoins (26.5% vs. 21.2%, both p b 0.0001). Epilepsy diagnosis type on the index date was significantly different, with 18.2% of cases with partial seizures compared to 32.3% of controls and 61.6% and 41.3% with other epilepsy, respectively. Total allcause health-care costs in the 6-month preindex were slightly though significantly higher among cases (median $5954 vs. $5919, p = 0.0485).
Adherence to AED treatment in the 6-month follow-up period
In the 6-month follow-up period, both cases and controls demonstrated high rates of AED adherence (PDC on any AED), both with a mean PDC of 92% and median of 100%.
Number of seizures in the 6-month follow-up period (cases)
Among matched cases, the vast majority (75.8%) experienced a single seizure resulting in ER/inpatient care (i.e., the breakthrough seizure experienced at index) in the follow-up period; 17.4% experienced 2 seizures, and 6.8% experienced 3 or more seizures.
3.4. All-cause health-care resource utilization and costs in the 6-month follow-up period
In the 6-month follow-up period, all-cause health-care resource use was higher among matched cases compared to controls, and all-cause health-care costs were significantly higher among cases for almost all of the services assessed (Fig. 1, Tables 2 and 3 ). The number of unique AED classes used was similar between cases and controls (mean 1.9, median 2.0 both). While cases had significantly higher total outpatient pharmacy costs and higher AED medication costs per person, controls had significantly higher total non-AED pharmacy costs per person compared to cases. Cases experienced significantly higher rates of allcause hospitalizations (60.5% vs. 9.1% with ≥1 hospitalization) and ER visits (64.9% vs. 19.2% with ≥ 1 visit) compared to controls (both p b 0.0001). Almost all patients had ≥ 1 outpatient physician office visit (any specialty). Among patients with ≥1 outpatient physician office visit, cases had more visits per person compared to controls (mean 8.6 vs. 7.6 [median 6.0 vs. 5.0, p b 0.0001]).
Cases had higher mean total all-cause direct health-care costs per person compared to controls ($23,821 vs. $9989 [median $12,714 vs. $5095; p b 0.0001]). All-cause health-care costs were driven by inpatient costs for cases (mean inpatient costs comprised 57% of mean total costs for cases compared to 19% for controls). At the p b 0.0001 level, cases had higher mean total medical care costs, higher mean inpatient costs, and higher mean ER costs per person.
Among cases, all-cause health-care resource utilization in the 6-month follow-up period progressively increased with number of seizures (1, 2 and 3 +) as did all-cause health-care costs (Fig. 1 , Tables 2 and 3) for almost all service categories assessed, including hospitalizations, ER visits, outpatient visits, and VNS surgery. Mean total costs per person doubled between patients with 1 and 2 seizures ($18,574 and $35,569) and increased 1.5 times between patients with 2 and 3 + seizures ($35,569 and $52,320). Costs were primarily driven by medical care and specifically by hospitalizations. Mean medical care costs increased with number of seizures ($15,149 to $48,284) and comprised 82% to 92% of mean total health-care costs.
Epilepsy-related resource utilization and costs in the 6-month follow-up period
Epilepsy-related resource use in the 6-month follow-up period was higher among matched cases compared to controls, and epilepsyrelated costs were significantly higher for all services assessed (Fig. 1 Fig. 1 . Total unadjusted health-care utilization: proportion with inpatient and ER visits, all-cause and epilepsy-related, in the 6-month follow-up period for cases and controls. . Epilepsy-related healthcare costs were driven by inpatient costs for cases with mean inpatient costs comprising 65% of total costs for cases and 14% for controls. Conversely, outpatient AED pharmacy costs represented 54% of total epilepsy-related health-care costs for controls and 15% for cases. Cases had higher mean medical care costs, higher mean inpatient costs, higher mean ER costs, and higher outpatient AED pharmacy costs per person (all p b 0.0001). Epilepsy-related costs represented 61% of total allcause costs for cases and 32% for controls.
Adjusted costs
After adjusting for baseline covariates in the GEE models, cases were associated with 2.3 times higher all-cause costs and 8.1 times higher epilepsy-related costs compared to controls in the 6-month follow-up period (both p b 0.0001) ( Table 5 ). The use of a single AED therapeutic class in the 6-month preindex was associated with 28.4% lower a Comparisons between matched controls and matched cases performed using chi-square testing for categorical variables and the Wilcoxon rank-sum test on the median for continuous variables.
Table 3
Total unadjusted all-cause health-care costs for cases and controls in the 6-month follow-up period. all-cause costs and 31.1% lower epilepsy-related costs compared to the use of 2 or more AED classes (both p b 0.0001). Several baseline comorbidities were significantly associated with higher all-cause costs including other pain and depression.
Discussion
Our analysis uncovered a substantial clinical and economic burden among AED-adherent patients with epilepsy in the 6-month period following the first ER/inpatient-treated breakthrough seizure (versus matched controls). Despite consistent treatment with AEDs, patients with breakthrough seizures utilized significantly more resources and had significantly higher costs than patients without breakthrough seizures, with double the mean total all-cause unadjusted direct health-care costs per person and 4.5 times higher mean total epilepsyrelated health-care costs per person. Additionally, all-cause healthcare utilization and costs increased with each subsequent seizure.
Adjusted analyses corroborated the unadjusted findings, and patients with breakthrough seizures were associated with 2.3 times higher allcause costs and 8.1 times higher epilepsy-related costs compared to controls.
In unadjusted analyses, the burden of breakthrough seizures was primarily driven by inpatient costs, which represented 57% of total costs for patients with breakthrough seizures compared to 19% for controls. Epilepsy-related inpatient costs represented 69% and 24% of all-cause inpatient costs for patients with breakthrough seizures vs. controls, respectively, demonstrating the impact of epilepsy on inpatient resource use and costs following a breakthrough seizure. Further, epilepsy and convulsions accounted for more than 70% of the top inpatient principal diagnoses for cases. More research is needed to understand the cost drivers at the inpatient level and whether the increase in inpatient costs is related to managing seizure activity or the potential causes (e.g., malignancy or arteriovenous malformations) or consequences (e.g., trauma) of the seizures. a Comparisons between matched controls and matched cases performed using chi-square testing for categorical variables and the Wilcoxon rank-sum tests on the median. Table 5 Generalized estimating equation (GEE) regression models of all-cause costs and epilepsy-related costs in the 6-month follow-up period. a Cases and controls were propensity score matched on age group, gender (although not significant), payer type, baseline CCI score, physician specialty, diagnosis of essential hypertension in the preindex period, and preindex health-care costs. Therefore, these characteristics were not included in the GEE model.
An average direct annual cost of $10,258 (2005 USD) has been found among privately insured patients with epilepsy in the US [12] . Our study uncovered substantially higher average 6-month costs postbreakthrough seizures among treatment-adherent cases ($23,821). Our study focus on the 6-month period postbreakthrough seizure may capture a period of heightened and costly health-care activity towards restoring control, which would likely decrease over time for those who achieve seizure control. Inpatient care was the primary cost driver among our cases, representing 57% of mean total costs; outpatient care was the primary cost component for our controls (44%) as well as the general epilepsy population (34%), demonstrating the substantial economic burden of inpatient care associated with breakthrough seizures. The 6-month cost among our controls ($9989) was slightly lower than the annual cost found overall for patients with epilepsy, suggesting that our patients with treatment-adherent breakthrough seizures and matched controls have different demographic and clinical characteristics (required adherence, clinically less healthy etc.) compared to the overall epilepsy population, further supported by baseline differences between unmatched cases and controls. Additionally, the requirement of ≥ 80% AED adherence during the 6-month preindex may have resulted in a sample with higher baseline pharmacy costs.
While we did not conduct direct comparisons of preindex and postindex costs for patients with breakthrough seizures, the direction of our results are consistent with the findings from Zachry et al. [17] . Costs in the 6-month pre-and postepilepsy-related emergent care episode were compared among AED-adherent patients. Postepisode mean all-cause costs were significantly higher than preepisode costs ($22,813 and $14,760; 2006 USD) and similar to our respective findings among cases ($23,821 and $13,693, respectively). Among our controls, mean all-cause 6-month postindex costs ($9989) decreased from mean 6-month preindex costs ($11,312), supporting other studies which have found that costs decrease over time among patients with epilepsy [13] . Specifically, patients will incur costs related to initial diagnosis and treatment, which will significantly decrease over time, particularly among those who achieve adequate seizure control through proper AED therapy.
In our study, there was a 2.8 times increase in mean all-cause costs between patients with 1 seizure (i.e., the breakthrough seizure) and 3+ seizures in the 6-month postbreakthrough seizure. This is consistent with a prior study which found a 2.2-fold difference in 4-year epilepsyrelated medical costs between patients with a single seizure at onset and those having recurrent seizures at the rate of more than one per month, after controlling for seizure type, age, gender, and ethnicity [13] .
Previous retrospective studies have looked at changes in AED therapy as an indicator of inadequate seizure control. Manjunath et al. found that mean annualized, total direct health-care costs (2009 USD) were higher in commercially insured patients with uncontrolled epilepsy (defined as ≥ 2 changes in AED therapy, followed by ≥ 1 epilepsyrelated ED visit/hospitalization within 1 year) vs. patients with wellcontrolled epilepsy: $24,853 vs. $9005, and similar to our analysis, hospitalizations represented the largest cost item for patients with uncontrolled seizures and were the main cost difference between matched cohorts [16] . Additionally, epilepsy-related medical costs comprised 41.1% of all-cause medical costs for the patients with uncontrolled seizures, compared to 61.1% among our cases, further demonstrating the epilepsy-related medical burden. Cramer et al. compared commercially insured patients with uncontrolled epilepsy (defined as addition of an AED to an existing regimen) and stable epilepsy and found that annual total costs ($23,238 vs. $13,839) and epilepsy-related ($12,399 vs. $5511) costs were higher in patients with uncontrolled epilepsy [15] . While outpatient costs were the primary cost component of total costs (36.4% for patients with uncontrolled epilepsy and 38.9% for patients with stable epilepsy), epilepsy-related costs comprised the majority of total costs for patients with uncontrolled seizures (53.4% and 39.8%, respectively). Chen et al. compared commercially insured patients with POS with and without refractory epilepsy (defined as use of ≥3 AEDs in a calendar year) [14] . Mean annual health-care costs (2008 USD) for patients with treatment-refractory seizures were significantly higher than that for patients without treatment-refractory seizures ($33,613 vs. $19,085); however, outpatient costs comprised the majority of costs ($13,431 vs. $8637). While recognizing the differences in study design, compared to these three study findings, the 6-month postbreakthrough seizure costs we identified are similar to the annualized and annual costs of commercially insured patients with uncontrolled epilepsy, respectively [15, 16] , and 70% of the annual costs for patients with treatment-refractory POS [17] , supporting the substantial economic impact immediately following a breakthrough seizure.
Results from this case-control study should be interpreted with caution and in context with results from other studies, because they can only establish associations and not cause-and-effect relationships. A few limitations are inherent to the use of administrative claims data. First, administrative claims databases cannot provide as much clinical detail and accuracy as medical records as they are collected for the purpose of reimbursement. Diagnoses may be recorded erroneously by clinicians or coders or may be used as rule outs. Epilepsy diagnoses may be recorded as a secondary diagnosis on a medical claim which is unrelated to the patient's epilepsy status. No assumptions can be made about the consumption of all of the medication supplied in each prescription on time; however, if a patient consistently fills a prescription, it is more likely that he/she is consistently consuming the medication. Pharmacy claims lack the patient's diagnosis, and some AEDs may be used for nonepilepsy indications; however, our requirements for both an epilepsy diagnosis and AED adherence likely rule out nonepilepsy indications. It is also possible that a patient may choose to go outside of his or her plan to purchase health-care services or pharmacy, and even AED pharmacy, and pay out-of-pocket. However, we believe this is less likely given the eligibility requirements for patients to have continuous health plan coverage. Nevertheless, claims data allow for a holistic view of patient interactions with the health-care system.
A few limitations are related to the study design. First, a few significant differences remained between cases and controls following the matching process. While these remaining differences may have inflated the cost estimates among cases relative to controls, it is reflective of the substantial increase in disease burden associated with the occurrence of breakthrough seizures and the resulting difficulty to perfectly match "sicker" cases to "healthier" controls. Further, while we were unable to control for duration and severity of illness, matching on other baseline characteristics (such as CCI) may have mitigated some of these inherent differences. Second, the ability to identify epileptic breakthrough seizures is also limited using claims databases, given the lack of confirmatory medical record data to understand the reason of admission. As there is no recognized definition or specific diagnosis code for a breakthrough seizure, we developed a standard, working definition, based on a review of the literature and clinician input, to apply to all patients. It is important to note that we cannot be certain that the episode of epilepsy-related inpatient/ER care was due to a breakthrough seizure. It is possible that the episode was related to some other destabilizing factor such as an adverse drug side effect or a more extensive diagnostic workup. However, our analysis required a primary epilepsy diagnosis similar to the analysis of Zachry et al. to provide greater confidence that a seizure was the cause of the emergent care episode rather than some other event [19] . Further research may be needed to develop this definition.
It is important to note that our analysis captured only a subset of the broader group of patients that experience breakthrough seizures, and our approach may underestimate the burden of breakthrough seizures for different reasons: a) we did not capture seizure events as a secondary diagnosis (e.g., where a traumatic event, such as fracture, is caused by a seizure and is coded as the primary diagnosis); and b) we did not identify patients who may have experienced seizures but did not receive inpatient/ER care. Factors which may impact the decision to receive inpatient/ER care include history of seizures and years diagnosed, severity of the seizure, comorbidities, general health and age, and patient preference for type of follow-up. However, our cases may have been biased towards higher costs due to our breakthrough seizure definition. Controls were not allowed to have an inpatient/ER admission with a primary diagnosis of epilepsy or convulsions, and it is likely that patients with significant resource utilization and costs are those who require inpatient/ER care.
Finally, the study sample may not be representative of the overall epilepsy population. We focused our analysis on a treatment-adherent population (that would be biased towards higher pharmacy costs), necessary to provide greater confidence that true breakthrough seizures were being observed, rather than seizures due to noncompliance. In addition, our population was largely comprised of commercially insured patients; thus, the results of our analysis may not be generalizable to patients who are uninsured or covered by other payers. Our continuous eligibility requirements, necessary to provide sufficient visibility into the patient's clinical history and follow-up period, exclude patients who may have disenrolled from their plan (due to changes in employment or health status) or died during this period, thereby potentially biasing the analysis towards a healthier sample. Our population with continuous health plan coverage may be biased towards higher health-care utilization and costs as a function of having coverage, compared to patients without continuous health plan coverage. Further, our results are based on an overall population with epilepsy. Outcomes may vary by individual seizure type, and a comparison of two recent publications demonstrate higher average annual costs among patients with POS ($11,276) compared to patients overall with epilepsy ($10,258) [12, 20] . Thus, our findings may not be applicable to specific seizure types.
Conclusion
While the true incidence of breakthrough seizures is unknown, breakthrough seizures were frequent in our study. Breakthrough seizures occurred among 28.4% of our study population of AED-adherent patients. Our study provides new insights into the occurrence and frequency of breakthrough seizures as well as their substantial healthcare resource utilization and direct cost impact among patients with epilepsy who are treatment-adherent. These findings suggest that more research is needed towards improving seizure control, via optimal management and the use of effective AED therapy, which can potentially lower costly hospitalizations, while improving patient outcomes and reducing costs.
